Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.
Saved in:
| Title: | Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species. |
|---|---|
| Authors: | Chang XL; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Reed JS; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Webb GM; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Wu HL; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Le J; Quest Clinical Research, San Francisco, California, United States of America., Bateman KB; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Greene JM; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Pessoa C; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Waytashek C; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Weber WC; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Hwang J; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Fischer M; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Moats C; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Shiel O; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Bochart RM; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Crank H; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Siess D; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Giobbi T; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Torgerson J; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Agnor R; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Gao L; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Dhody K; Amarex Clinical Research LLC, Germantown, Maryland, United States of America., Lalezari JP; Quest Clinical Research, San Francisco, California, United States of America., Bandar IS; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America., Carnate AM; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America., Pang AS; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America., Corley MJ; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America., Kelly S; CytoDyn Inc., Vancouver, Washington, United States of America., Pourhassan N; CytoDyn Inc., Vancouver, Washington, United States of America., Smedley J; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Bimber BN; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America., Hansen SG; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America., Ndhlovu LC; Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America., Sacha JB; Vaccine & Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2022 Mar 31; Vol. 18 (3), pp. e1010396. Date of Electronic Publication: 2022 Mar 31 (Print Publication: 2022). |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1553-7374 |
|---|---|
| DOI: | 10.1371/journal.ppat.1010396 |
